Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
51
SOPH Quote, Financials, Valuation and Earnings
Last price:
$4.54
Seasonality move
:
5.53%
Day range:
$4.50 - $4.61
52-week range:
$2.58 - $5.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.21x
P/B ratio:
5.14x
Volume:
24.8K
Avg. volume:
84.8K
1-year change:
45.57%
Market cap:
$312.1M
Revenue:
$65.2M
EPS (TTM):
-$1.12
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SOPH
SOPHiA GENETICS SA
|
$18.1M | -$0.20 | 15.57% | -12.05% | $7.33 |
|
ACIU
AC Immune SA
|
$994.8K | -$0.22 | 18.61% | -6.92% | $9.01 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$9M | -$1.29 | -89.16% | -180.62% | $81.33 |
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $0.86 | 29.38% | -70.04% | $400.06 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SOPH
SOPHiA GENETICS SA
|
$4.60 | $7.33 | $312.1M | -- | $0.00 | 0% | 4.21x |
|
ACIU
AC Immune SA
|
$3.12 | $9.01 | $313.9M | -- | $0.00 | 0% | 60.84x |
|
ADXN
Addex Therapeutics Ltd.
|
$8.89 | $30.00 | $11M | 0.77x | $0.00 | 0% | 40.66x |
|
CRSP
CRISPR Therapeutics AG
|
$56.71 | $81.33 | $5.4B | -- | $0.00 | 0% | 129.35x |
|
ONC
BeOne Medicines Ltd.
|
$311.73 | $400.06 | $34.5B | 599.83x | $0.00 | 0% | 6.96x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SOPH
SOPHiA GENETICS SA
|
51.08% | 1.943 | 19.62% | 2.45x |
|
ACIU
AC Immune SA
|
6.95% | 3.999 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 2.172 | 0.5% | 1.91x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 3.188 | 3.47% | 16.13x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | 0.334 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SOPH
SOPHiA GENETICS SA
|
$12.9M | -$17.3M | -57.5% | -86.58% | -88.76% | -$13.2M |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
SOPHiA GENETICS SA vs. Competitors
-
Which has Higher Returns SOPH or ACIU?
AC Immune SA has a net margin of -102.87% compared to SOPHiA GENETICS SA's net margin of -1688.87%. SOPHiA GENETICS SA's return on equity of -86.58% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital SOPHSOPHiA GENETICS SA66.32% -$0.30 $124.1M ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About SOPH or ACIU?
SOPHiA GENETICS SA has a consensus price target of $7.33, signalling upside risk potential of 59.42%. On the other hand AC Immune SA has an analysts' consensus of $9.01 which suggests that it could grow by 186.4%. Given that AC Immune SA has higher upside potential than SOPHiA GENETICS SA, analysts believe AC Immune SA is more attractive than SOPHiA GENETICS SA.
Company Buy Ratings Hold Ratings Sell Ratings SOPHSOPHiA GENETICS SA4 0 0 ACIUAC Immune SA4 0 0 -
Is SOPH or ACIU More Risky?
SOPHiA GENETICS SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.243%.
-
Which is a Better Dividend Stock SOPH or ACIU?
SOPHiA GENETICS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SOPHiA GENETICS SA pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOPH or ACIU?
SOPHiA GENETICS SA quarterly revenues are $19.5M, which are larger than AC Immune SA quarterly revenues of $1.2M. SOPHiA GENETICS SA's net income of -$20M is lower than AC Immune SA's net income of -$19.8M. Notably, SOPHiA GENETICS SA's price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SOPHiA GENETICS SA is 4.21x versus 60.84x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOPHSOPHiA GENETICS SA4.21x -- $19.5M -$20M ACIUAC Immune SA60.84x -- $1.2M -$19.8M
-
Which has Higher Returns SOPH or ADXN?
Addex Therapeutics Ltd. has a net margin of -102.87% compared to SOPHiA GENETICS SA's net margin of -3178.71%. SOPHiA GENETICS SA's return on equity of -86.58% beat Addex Therapeutics Ltd.'s return on equity of -73.84%.
Company Gross Margin Earnings Per Share Invested Capital SOPHSOPHiA GENETICS SA66.32% -$0.30 $124.1M ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M -
What do Analysts Say About SOPH or ADXN?
SOPHiA GENETICS SA has a consensus price target of $7.33, signalling upside risk potential of 59.42%. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 258%. Given that Addex Therapeutics Ltd. has higher upside potential than SOPHiA GENETICS SA, analysts believe Addex Therapeutics Ltd. is more attractive than SOPHiA GENETICS SA.
Company Buy Ratings Hold Ratings Sell Ratings SOPHSOPHiA GENETICS SA4 0 0 ADXNAddex Therapeutics Ltd.0 0 0 -
Is SOPH or ADXN More Risky?
SOPHiA GENETICS SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.573, suggesting its more volatile than the S&P 500 by 57.32%.
-
Which is a Better Dividend Stock SOPH or ADXN?
SOPHiA GENETICS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SOPHiA GENETICS SA pays -- of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOPH or ADXN?
SOPHiA GENETICS SA quarterly revenues are $19.5M, which are larger than Addex Therapeutics Ltd. quarterly revenues of $62K. SOPHiA GENETICS SA's net income of -$20M is lower than Addex Therapeutics Ltd.'s net income of -$2M. Notably, SOPHiA GENETICS SA's price-to-earnings ratio is -- while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SOPHiA GENETICS SA is 4.21x versus 40.66x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOPHSOPHiA GENETICS SA4.21x -- $19.5M -$20M ADXNAddex Therapeutics Ltd.40.66x 0.77x $62K -$2M
-
Which has Higher Returns SOPH or CRSP?
CRISPR Therapeutics AG has a net margin of -102.87% compared to SOPHiA GENETICS SA's net margin of -11973.12%. SOPHiA GENETICS SA's return on equity of -86.58% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital SOPHSOPHiA GENETICS SA66.32% -$0.30 $124.1M CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About SOPH or CRSP?
SOPHiA GENETICS SA has a consensus price target of $7.33, signalling upside risk potential of 59.42%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 43.42%. Given that SOPHiA GENETICS SA has higher upside potential than CRISPR Therapeutics AG, analysts believe SOPHiA GENETICS SA is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings SOPHSOPHiA GENETICS SA4 0 0 CRSPCRISPR Therapeutics AG12 10 1 -
Is SOPH or CRSP More Risky?
SOPHiA GENETICS SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.
-
Which is a Better Dividend Stock SOPH or CRSP?
SOPHiA GENETICS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SOPHiA GENETICS SA pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOPH or CRSP?
SOPHiA GENETICS SA quarterly revenues are $19.5M, which are larger than CRISPR Therapeutics AG quarterly revenues of $889K. SOPHiA GENETICS SA's net income of -$20M is higher than CRISPR Therapeutics AG's net income of -$106.4M. Notably, SOPHiA GENETICS SA's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SOPHiA GENETICS SA is 4.21x versus 129.35x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOPHSOPHiA GENETICS SA4.21x -- $19.5M -$20M CRSPCRISPR Therapeutics AG129.35x -- $889K -$106.4M
-
Which has Higher Returns SOPH or ONC?
BeOne Medicines Ltd. has a net margin of -102.87% compared to SOPHiA GENETICS SA's net margin of 8.84%. SOPHiA GENETICS SA's return on equity of -86.58% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital SOPHSOPHiA GENETICS SA66.32% -$0.30 $124.1M ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About SOPH or ONC?
SOPHiA GENETICS SA has a consensus price target of $7.33, signalling upside risk potential of 59.42%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $400.06 which suggests that it could grow by 28.34%. Given that SOPHiA GENETICS SA has higher upside potential than BeOne Medicines Ltd., analysts believe SOPHiA GENETICS SA is more attractive than BeOne Medicines Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SOPHSOPHiA GENETICS SA4 0 0 ONCBeOne Medicines Ltd.18 1 1 -
Is SOPH or ONC More Risky?
SOPHiA GENETICS SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.
-
Which is a Better Dividend Stock SOPH or ONC?
SOPHiA GENETICS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SOPHiA GENETICS SA pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOPH or ONC?
SOPHiA GENETICS SA quarterly revenues are $19.5M, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. SOPHiA GENETICS SA's net income of -$20M is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, SOPHiA GENETICS SA's price-to-earnings ratio is -- while BeOne Medicines Ltd.'s PE ratio is 599.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SOPHiA GENETICS SA is 4.21x versus 6.96x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOPHSOPHiA GENETICS SA4.21x -- $19.5M -$20M ONCBeOne Medicines Ltd.6.96x 599.83x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
